Medicine:Neuromuscular medicine

From HandWiki
Short description: Specialty of medicine that focuses on neuromuscular diseases

Neuromuscular medicine is a subspecialty of neurology and physiatry that focuses the diagnosis and management of neuromuscular diseases. The field encompasses issues related to both diagnosis and management of these conditions, including rehabilitation interventions to optimize the quality of life of individuals with these conditions.[1] This field encompasses disorders that impact both adults and children and which can be inherited or acquired, typically from an autoimmune disease.[2] A neurologist or physiatrist can diagnose these diseases through a clinical history, examination, and electromyography including nerve conduction studies.  Many recent drug therapies have been developed to address the acquired neuromuscular diseases including but not limited to immune suppression and drugs that increase the neurotransmitters at the neuromuscular junction.[3][4]  Gene modifying therapies are also a recent treatment branch of neuromuscular medicine with advancements made in disorders such as spinal muscular atrophy and Duchenne muscular dystrophy.[5]  

See also

References

  1. "The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular disease". Physical Medicine and Rehabilitation Clinics of North America 23 (3): 475–493. August 2012. doi:10.1016/j.pmr.2012.06.010. PMID 22938874. 
  2. "Neuromuscular Diseases". Seminars in Neurology 36 (5): 409–418. October 2016. doi:10.1055/s-0036-1586263. PMID 27704495. 
  3. "Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease". Annals of Neurology 35 (3): 260–268. March 1994. doi:10.1002/ana.410350304. PMID 8122878. 
  4. "Myasthenia gravis: subgroup classification and therapeutic strategies". The Lancet. Neurology 14 (10): 1023–1036. October 2015. doi:10.1016/S1474-4422(15)00145-3. PMID 26376969. 
  5. "Current Clinical Applications of In Vivo Gene Therapy with AAVs". Molecular Therapy 29 (2): 464–488. February 2021. doi:10.1016/j.ymthe.2020.12.007. PMID 33309881.